Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 4131-4140 of 11530

Edit search filters
  1. A Study Of NT-175 In Adult Subjects With Unresectable, Advanced, And/or Metastatic Solid Tumors That Are Positive For HLA-A*02:01 And The TP53 R175H Mutation

    Jacksonville, FL

  2. A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. Research With I-124 EVuzamitide To Elucidate Cardiac AmyLoidosis

    Scottsdale/Phoenix, AZ

  4. A Study Of Prehabilitation In Patients With Multiple Myeloma Receiving CAR-T Therapy

    Rochester, MN

  5. JUST BREATHE, Breathing Life Into Innovative Therapies For ARDS (Master Record)

    Rochester, MN

  6. A Study Of Vaginal Cuff Closure Direction On Surgical Outcomes And Patient-reported Pelvic Dysfunction

    Scottsdale/Phoenix, AZ

  7. Treatment Of AA Amyloidosis

    Rochester, MN

  8. Testing The Addition Of An Anti-Cancer Drug, Gemcitabine, To Usual Treatment (BCG Alone) In People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer